Advanced Solid Tumor
Conditions
Keywords
metastatic, advanced disease, phase I
Brief summary
The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib. This study will also look at the toxicity of the combination of rapamycin and sorafenib and the antitumor activity of the combination in subjects with advanced cancers.
Interventions
DRUGSorafenib
400mg BID (200 mg twice daily)
DRUGRapamycin
30mg once weekly
Sponsors
Bayer
University of Chicago
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Solid cancer for which curative measures have failed or for which there is no known superior treatment * ECOG performance status 0-2 * Measurable or non-measurable disease * Life expectancy of greater than 12 weeks and no anticipated need for other antineoplastic therapy in the next 4 weeks * Age 18 years or older * Patients must have adequate organ and marrow function as defined below: * ALT and AST less than or equal to 2.5 x the ULN (\< 5 x ULN for patients with liver involvement). * hemoglobin greater than or equal to 9 g/dL * absolute neutrophil count greater than or equal to 1,500/μL * platelets greater than or equal to 100,000/μL (greater than or equal to 35,000/μL without transfusion for patients with CLL/SLL or follicular lymphoma) * total bilirubin less than or equal to 1.5 x ULN * creatinine less than or equal to 1.5 x ULN * Women of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment. * Ability to understand and the willingness to sign a written informed consent document * Must not have any evidence of bleeding diathesis.
Exclusion criteria
* Patients who have had chemotherapy or immunotherapy within 3 weeks or radiotherapy within 14 days prior to entering the study * Patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy * Patients with uncontrolled brain metastases. * Concurrent illness or medication exclusions * HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with sorafenib or rapamycin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic interactions | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Response Rate | 8 weeks |
Countries
United States
Outcome results
None listed